The hydrogen/deuterium-exchange (H/D-Ex) phenomenon is well established as a method for measuring binding interactions between a drug target and a ligand. ExSAR Corp. has developed an automated, rapid, and sensitive H/D-Ex system to rapidly map drug-target interactions in solution, for use in small-molecule drug discovery and also to assist in the stabilization and design of new protein therapeutics.
11 Deer Park Dr., Suite 103
Monmouth Junction, NJ 08852
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.
Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.
